Experimental drug shows efficacy in lowering glucose levels

02/26/2012 | Bloomberg

A study published in The Lancet showed 48% of type 2 diabetes patients who took Takeda Pharmaceuticals' TAK-875 for 12 weeks achieved blood glucose levels below a predetermined level, compared with 40% of those who received glimepiride. Researchers also found that 2% of patients who took TAK-875 developed hypoglycemia, compared with 19% in the glimepiride group.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI